Emerging therapeutics in pulmonary hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary hypertension (PH) is a progressive, often fatal disease characterized by elevated pulmonary pressures.
• Endothelial dysfunction drives vascular remodeling, increasing pulmonary vascular resistance.
• Current FDA-approved treatments exist for pulmonary arterial hypertension (PAH) and chronic thromboembolic PH, but morbidity and mortality remain high.

Purpose of the Study:

• To provide an updated overview of novel therapeutic strategies for PH.
• To focus on emerging treatments for PAH, the most studied form of PH.
• To offer guidelines for future research in PH therapeutics.

Main Methods:

• Review of recent scientific literature and clinical studies.
• Analysis of molecular targets mediating vasodilation, anti-inflammatory, and antifibrotic effects.
• Synthesis of current understanding of PH pathophysiology and treatment landscape.

Main Results:

• Identification of promising molecular targets for PH treatment.
• Exploration of novel therapeutic approaches beyond current standards of care.
• Highlighting the need for expanded treatment options for non-PAH groups.

Conclusions:

• Emerging research offers potential for new PH therapies targeting specific molecular pathways.
• Further investigation is crucial to develop effective treatments for all forms of PH.
• Future studies should guide the clinical translation of these novel approaches.